After previous disappointments with BTK inhibitors, a novel drug in this class is the first to show superiority to an active ...
Antibiotic resistance continues to push modern medicine into dangerous territory. In hospitals around the world, infections ...
Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...
The approval was based on data from the phase 3 ULTIMATE 1 and ULTIMATE 2 trials that compared ublituximab-xiiy to teriflunomide in patients with relapsing multiple sclerosis. The Food and Drug ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Tyruko, the first biosimilar to Tysabri injection, for the treatment of adults with ...
For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology. Izanne Roos, M.B.Ch.B., ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...
A breakthrough in monkey malaria research could help scientists diagnose and treat a relapsing form of human malaria. A breakthrough in monkey malaria research by two University of Otago scientists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results